Trial Profile
A Phase 2 Intensification Study of BIT225, a Human Immunodeficiency Virus-1 Vpu Inhibitor, in HIV-1 Infected Individuals Initiating Combination Antiretroviral Therapy (cART).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Apr 2020
Price :
$35
*
At a glance
- Drugs BIT 225 (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors Biotron
- 11 Mar 2020 Results presented at the 27th Conference on Retroviruses and Opportunistic Infections.
- 01 Mar 2018 Status changed from active, no longer recruiting to completed.
- 28 Aug 2017 According to a Biotron media release, the trial is in progress and scheduled for completion in the second half of 2017.